Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P. V., Kanaani, Z. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.19623 · Cited by 168

Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar

Hasan, M. R., Kalikiri, M. K. R., Mirza, F., Sundararaju, S., Sharma, A., Xaba, T., Lorenz, S., Chemaitelly, H. S., Kahlout, R. A. E., Tsui, C. K. M., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.006 · Cited by 65

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants

Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209306 · Cited by 144

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150

A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease

Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00058-0 · Cited by 111

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

Chemaitelly, H. S., Nagelkerke, N. J. D., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Kanaani, Z. A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac109 · Cited by 108

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

(2022) · doi:10.1038/s41467-022-32363-4 · Cited by 84

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2211055 · Cited by 77

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00287-7 · Cited by 76

Covid-19 Vaccine Protection among Children and Adolescents in Qatar

Chemaitelly, H. S., AlMukdad, S., Ayoub, H. H., Altarawneh, H. N., Coyle, P. V., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210058 · Cited by 72

Protection against Omicron from Vaccination and Previous Infection in a Prison System

Chin, E. T., Leidner, D., Lamson, L., Lucas, K. D., Studdert, D. M., Goldhaber‐Fiebert, J. D., Andrews, J. R., & Salomon, J. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2207082 · Cited by 65

Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Nature · doi:10.1038/s41586-024-08511-9 · Cited by 61

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study

Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104734 · Cited by 58

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar

Tayar, E., Abdeen, S., Alah, M. A., Chemaitelly, H. S., Bougmiza, I. M., Ayoub, H. H., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Al‐Romaihi, H. E., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.016 · Cited by 44

Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design

Ayoub, H. H., Tomy, M., Chemaitelly, H. S., Altarawneh, H. N., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad239 · Cited by 40

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Yassine, H. M., Khatib, H. A. A., Smatti, M. K., Coyle, P., Kanaani, Z. A., et al. (2022) · doi:10.1101/2022.02.07.22270568 · Cited by 30

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

Choueiri, T. K., Labaki, C., Bakouny, Z., Hsu, C., Schmidt, A. L., Lopes, G. D. L., Jr., Hwang, C., Singh, S. R. K., Jani, C., Weissmann, L. B., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100445 · Cited by 39

Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study

Chemaitelly, H. S., Faust, J. S., Krumholz, H. M., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.005 · Cited by 38

Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

Qassim, S. H., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102102 · Cited by 32

Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers

Ntziora, F., Kostaki, E. G., Karapanou, Α., Mylona, M., Tseti, I. K., Sipsas, N. V., Paraskevis, D. N., & Sfikakis, P. P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.042 · Cited by 29

Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · eLife · doi:10.7554/elife.103690 · Cited by 26

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31

A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains

Zhang, Z., He, Q., Zhao, W., Li, Y., Yang, J., Hu, Z., Chen, X., Peng, H., Fu, Y., Chen, L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144164 · Cited by 22

Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents

Kim, Y.-Y., Choe, Y. J., Kim, J., Kim, R. K., Jang, E. J., Park, S. K., Lim, D., Yi, S., Lee, S., Kwon, G., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2811.220918 · Cited by 22

Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

Chemaitelly, H. S., Coyle, P. V., Kacem, M. A. B. H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Journal of Travel Medicine · doi:10.1093/jtm/taae053 · Cited by 21

Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression

Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02663-z · Cited by 23

History of primary-series and booster vaccination and protection against Omicron reinfection

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0761 · Cited by 30

Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022

Kim, S. S., Chung, J. R., Talbot, H. K., Grijalva, C. G., Wernli, K. J., Kiniry, E. L., Martin, E. T., Monto, A. S., Belongia, E. A., McLean, H. Q., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13029 · Cited by 22

COVID-19 Vaccination in Korea

Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19

Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia

Spinardi, J., Dantas, A. C., Carballo, C. M., Thakkar, K. B., Akoury, N. A., Kyaw, M. H., Morales, G. D. C., Srivastava, A. K., & Sáfadi, M. A. P. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00804-2 · Cited by 19

Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis

Tsang, T. K., Sullivan, S. G., Huang, X., Wang, C., Wang, Y., Nealon, J., Yang, B., Ainslie, K. E. C., & Cowling, B. J. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae142 · Cited by 21

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic

Bian, D. J. H., Sabri, S., & Abdulkarim, B. (2022) · Cancers · doi:10.3390/cancers14153598 · Cited by 21

SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies

Beukenhorst, A. L., Koch, C. M., Hadjichrysanthou, C., Alter, G., de Wolf, F., Anderson, R. M., & Goudsmit, J. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00965-x · Cited by 18

Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination

Bullock, J. L., Hickey, T. E., Kemp, T. J., Metz, J. B., Loftus, S. A., Haynesworth, K., Castro, N. D., Luke, B. T., Lowy, D. R., & Pinto, L. A. (2024) · Vaccines · doi:10.3390/vaccines12050516 · Cited by 16

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

Qassim, S. H., Hasan, M. R., Tang, P., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., Nasrallah, G. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984784 · Cited by 19

Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient

Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 17

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations

Trombetta, C. M., Piccini, G., Pierleoni, G., Leonardi, M., Dapporto, F., Marchi, S., Andreano, E., Paciello, I., Benincasa, L., Lovreglio, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03849-0 · Cited by 13

Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study

Chung, H., Austin, P. C., Brown, K. A., Buchan, S. A., Fell, D. B., Fong, C. H., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac449 · Cited by 15

Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis

Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · BMC Medicine · doi:10.1186/s12916-022-02600-0 · Cited by 14

COVID-19 primary series and booster vaccination and potential for immune imprintingPreprint

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.10.31.22281756 · Cited by 14

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

Liu, C., Wang, L., Merriam, J. S., Shi, W., Yang, E. S., Zhang, Y., Chen, M., Kong, W., Cheng, C., Tsybovsky, Y., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00707-w · Cited by 14

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

Mahmoud, M., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13224 · Cited by 12

Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice

Mukesh, R. K., Hill, T., Kaiser, F. K., Prado-Smith, J., Schulz, J. E., Gallogly, S., Herbold, L., Bauer, K., Smith, B. J., Myers, L. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06880-3 · Cited by 12

Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records

Atanasov, V. A., Barreto, N., Whittle, J., Meurer, J., Weston, B. W., Luo, Q., Yuan, A. Y., Franchi, L., Zhang, R., & Black, B. S. (2023) · Vaccines · doi:10.3390/vaccines11050971 · Cited by 11

Singing Is a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case-Control Study of Karaoke-Related Coronavirus Disease 2019 Outbreaks in 2 Cities in Hokkaido, Japan, Linked by Whole Genome Analysis

Nakashita, M., Takagi, Y., Tanaka, H., Nakamura, H., Serizawa, Y., Ukai, T., Azuma, K., Chiba, H., Terada, K., Nakanishi, K., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac158 · Cited by 12

Implications of COVID-19 vaccine effectiveness waning for public health

Odone, A., Vigezzi, G. P., & Baldanti, F. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00233-x · Cited by 12

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages

He, Q., Sun, S., Chen, X., Hu, Z., Zhang, Y., Peng, H., Fu, Y., Yang, J., & Chen, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010146 · Cited by 11

Safety and Immunogenicity of an mRNA-1273 Booster in Children

Berthaud, V., Creech, C. B., Rostad, C. A., Carr, Q. O., de Leon, L., Dietrich, M., Gupta, A. K., Javita, D., Nachman, S., Pinninti, S. G., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae420 · Cited by 9

Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings

Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10

Mapping the Arab genome

Mbarek, H., & Ismail, S. I. (2022) · Nature Genetics · doi:10.1038/s41588-022-01239-0 · Cited by 10

Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity

Choi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Kim, H. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035441 · Cited by 10

Effectiveness of mRNA Booster Vaccine Against Coronavirus Disease 2019 Infection and Severe Outcomes Among Persons With and Without Immune Dysfunction: A Retrospective Cohort Study of National Electronic Medical Record Data in the United States

Sun, J., Zheng, Q., Anzalone, A. J., Abraham, A. G., Olex, A. L., Zhang, Y., Mathew, J., Safdar, N., Haendel, M. A., Segev, D. L., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae019 · Cited by 9

BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13357 · Cited by 8

Real-world effectiveness of COVID-19 vaccines among Colombian adults: A retrospective, population-based study of the ESPERANZA cohort

Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 8

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine

Yong, X., Liu, J., Zeng, Y., Nie, J., Cui, X., Wang, T., Wang, Y., Chen, Y., Kang, W., Yang, Z., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2267869 · Cited by 8

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence

Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9

Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose

Moine, C. L., Soyfoo, M. S., Mekkaoui, L., Dahma, H., & Tant, L. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/ti3tvu · Cited by 9

Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP

Clemens, S. A. C., Fortaleza, C. M. C. B., Crowe, M., Tasca, K. I., Spadaro, A. G., Souza‐Neto, J. A., Grotto, R. M. T., Sider, R., Jimeno, J., Verstraeten, T., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1016402 · Cited by 8

A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses

Gordy, J. T., Hui, Y., Schill, C., Wang, T., Chen, F., Fessler, K., Meza, J., Li, Y., Taylor, A. D., Bates, R. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292059 · Cited by 6

COVID-19 Vaccines—All You Want to Know

Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6

COVID-19 Vaccination Recommendations for 2024–2025 in Korea

Park, W. B., Hwang, Y. H., Kwon, K. T., Noh, J. Y., Park, S. H., Song, J. Y., Choo, E. J., Choi, M. J., Choi, J. Y., Heo, J. Y., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2024.0142 · Cited by 6

Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar

Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf098 · Cited by 6

Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar

Chemaitelly, H. S., Akhtar, N., Jerdi, S. A., Kamran, S., Joseph, S., Morgan, D., Uy, R. S., Abid, F. B., Al‐Khal, A., Abou‐Samra, A., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596676 · Cited by 6

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study

He, X., Zeng, B., Wang, Y., Pang, Y., Zhang, M., Hu, T., Liang, Y., Kang, M., & Tang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257360 · Cited by 6

A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks

Jeong, Y. D., Ejima, K., Kim, K. S., Iwanami, S., Hart, W. S., Thompson, R. N., Jung, I. H., Iwami, S., Ajelli, M., & Aihara, K. (2025) · Communications Medicine · doi:10.1038/s43856-024-00716-3 · Cited by 5

The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2

Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5

Short- and longer-term all-cause mortality among SARS-CoV-2-infected persons and the pull-forward phenomenon in QatarPreprint

Chemaitelly, H. S., Faust, J. S., Krumholz, H. M., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., et al. (2023) · medRxiv · doi:10.1101/2023.01.29.23285152 · Cited by 5

Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection

Hwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily

Vella, G., Genovese, D., Belluzzo, M., Mazzeo, L., Pisciotta, V., & Amodio, E. (2023) · Healthcare · doi:10.3390/healthcare11030305 · Cited by 4

Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China

Guo, Y., Ye, W., Zhao, Z., Guo, X., Song, W., Su, Y., Zhao, B., Ou, J., Deng, Y., & Chen, T. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.02.002 · Cited by 4

Protection against reinfection with SARS-CoV-2 omicron BA.2.75 * sublineagePreprint

Chemaitelly, H. S., Tang, P., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Ayoub, H. H., Altarawneh, H. N., Kanaani, Z. A., et al. (2022) · medRxiv · doi:10.1101/2022.10.29.22281606 · Cited by 4

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infectionsPreprint

Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.21.23288917 · Cited by 4

Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar

Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19168-3 · Cited by 3

COVID-19 Vaccination Recommendations for 2025–2026 in Korea

Park, W. B., Hwang, Y. H., Kwon, K. T., Noh, J. Y., Park, S. H., Song, J. Y., Choo, E. J., Choi, M. J., Choi, J. Y., Heo, J. Y., et al. (2025) · Infection and Chemotherapy · doi:10.3947/ic.2025.0130 · Cited by 3

Immune histories and natural infection protection during the omicron era

Chemaitelly, H. S., Ayoub, H. H., Bobrovitz, N., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00974-9 · Cited by 3

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprintingPreprint

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.11.14.22282103 · Cited by 3

COVID‐19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Preprint

Black, B. S., & Thaw, D. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155493 · Cited by 3

Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127556 · Cited by 2

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2

Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses

Kumar, S., Lai, L., Ellis, M., Patel, A. B., Joshi, D., Velden, J. W. V., Faraj, J. A., Wimalasena, S., Pallavi, R. R., Iriss, J., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00749-26 · Cited by 2

Association of public health and social measures with vaccine effectiveness

Tsang, T. K., Sullivan, S. G., Huang, X., Wang, C., Li-ping, P., Yang, B., & Cowling, B. J. (2026) · Nature Health · doi:10.1038/s44360-026-00127-9 · Cited by 2

Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2

Dulin, H., Barre, R. S., Xu, D., Neal, A., Vizcarra, E. A., Chavez, J., Ulu, A., Yang, M., Khan, S. R., Wuang, K., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01571-23 · Cited by 2

Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination

Törnell, A., Wiktorin, H. G., Ringlander, J., Arabpour, M., Nilsson, S., Lindh, M., Lagging, M., Hellstrand, K., & Martner, A. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109248 · Cited by 2

Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA VaccinesPreprint

Choueiri, T. K., Labaki, C., Bakouny, Z., Hsu, C., Schmidt, A. L., Lopes, G. D. L., Jr., Hwang, C., Singh, S. R. K., Jani, C., Weissmann, L. B., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089485 · Cited by 2

Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities

Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002718 · Cited by 1

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

Younes, S. N., Nicolai, E., Pieri, M., Bernardini, S., Daas, H. I., Al‐Sadeq, D. W., Younes, N., Shurrab, F. M., Nizamuddin, P. B., Amanullah, F. H., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13290 · Cited by 3

Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1

Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysisPreprint

Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1571821/v2 · Cited by 1

Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infectionPreprint

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.11.29.22282864 · Cited by 1

Effectiveness of SARS‐CoV‐2 vaccines used in Malaysia: A systematic review and meta‐analysisPreprint

Thantry, A. D. K., Lakshmanan, P. A. P., Kunasakaran, D. A. L., & Shenq, E. C. (2023) · Research Square · doi:10.21203/rs.3.rs-2888103/v1 · Cited by 1

Usefulness of vaccine boosters for Covid-19 in Italy and in UK and comparison between in intensive care admissions and deaths of vaccinated and unvaccinated patients. Surprises and implications

Alessandria, M., Simion, C., & Donzelli, A. (2022) · F1000Research · doi:10.12688/f1000research.111023.1

A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: Observational study (Preprint)Preprint

Nguyen, N. T. H., Ou, T.-Y., Huy, L. Đ., Shih, C., Chang, Y.-M., Phuc, P. T., & Huang, C. (2022) · doi:10.2196/preprints.40263

Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysisPreprint

Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1571821/v1

A Tale of 2 mRNA Vaccines

Witberg, G., & Richter, I. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.010

Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

Younes, S. N., Nicolai, E., Younes, N., Pieri, M., Bernardini, S., Nizamuddin, P. B., Al‐Sadeq, D. W., Daas, H. I., Ismail, A. I. H. E., Yassine, H. M., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.06.010

The Effectiveness of COVID-19 Vaccines During the Pre-Omicron and Omicron Periods: A Retrospective Test-Negative Case–Control Study

Brambilla, R., Gili, R., Vigna‐Taglianti, F., Lenzi, J., Riccò, M., Burioni, R., Scarvaglieri, M., Rocco, R., Buttafuoco, V., Cristaudo, R. M. T. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12111245

Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic

Dave, N., van der Werff, S. D., Sjöholm, D., Zetterqvist, J., & Nauclér, P. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11349-9

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8057 · Cited by 239

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine

Debes, A. K., Xiao, S., Egbert, E. R., Caturegli, P., Gadala, A., Colantuoni, E., Sitaras, I., Pekosz, A. S., & Milstone, A. M. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02046-22 · Cited by 17

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

Suthar, M. (2022) · Data Archiving and Networked Services (DANS) · doi:10.17632/j6ds96cd5g